As shown in Figures 1(a)–1(c), TPL suppresses HER2 expression in the KB and OEC-M1 oral cancer cell lines; the MCF-7, BT-474, and MCF-7/HER breast cancer cell lines; and the SKOV-3, TOV-21G, and OVCAR-3 ovarian cancer cell lines. Here, ERBB2 is linked to breast carcinoma.